The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

Kanwal Raghav; John H. Strickler

doi:10.1001/jamaoncol.2019.2985

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

GI Medical Oncology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1511-1512
Number of pages	2
Journal	JAMA Oncology
Volume	5
Issue number	10
DOIs	https://doi.org/10.1001/jamaoncol.2019.2985
State	Published - Oct 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2019.2985

Cite this

@article{b871ae1cb809427c952a8497ac9c661d,

title = "The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer",

author = "Kanwal Raghav and Strickler, {John H.}",

year = "2019",

month = oct,

doi = "10.1001/jamaoncol.2019.2985",

language = "English (US)",

volume = "5",

pages = "1511--1512",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

AU - Raghav, Kanwal

AU - Strickler, John H.

PY - 2019/10

Y1 - 2019/10

UR - http://www.scopus.com/inward/record.url?scp=85070937208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070937208&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.2985

DO - 10.1001/jamaoncol.2019.2985

M3 - Letter

C2 - 31415062

AN - SCOPUS:85070937208

SN - 2374-2437

VL - 5

SP - 1511

EP - 1512

JO - JAMA Oncology

JF - JAMA Oncology

IS - 10

ER -

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this